Generating your feed, please be patient ...

Latest news

Zootzle IntelligenceImmunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial | medRxiv | Zootzle